| Patient | Wilma Rudolph |
|---|---|
| Date of birth | 1940-06-23 |
| Identifiers | MRN HR-ML036-SYN-TD; SSN (made up) 000-36-5170 |
| Document date | 1994-10-09 |
| Author | Gloria Haynes-Whitaker, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
MRI result after chemoradiation and the first day of adjuvant temozolomide. [S]
Ms. Rudolph returns four weeks after the end of radiotherapy. The MRI two days ago shows thin, smooth enhancement along the edge of the resection cavity and no new or nodular enhancement, with less swelling than after surgery. Her energy has improved over the past two weeks and she is working half days. The scalp has healed. She saw the palliative care team eleven days ago, talked through her symptoms, her understanding of the illness and what matters most to her, and completed an advance directive naming a health care agent. The tumor-treating fields device was fitted yesterday and she wore it overnight. She has had no headache, seizure, change in speech, weakness or fall. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| MRI | Treatment-related change only; no progression (RANO 2.0) |
| Energy | Improving; half days at work |
| Palliative care | Seen eleven days ago; advance directive completed |
| Today | Adjuvant temozolomide cycle 1, day 1; tumor-treating fields started |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired in the afternoons, less than before; no fever |
| Gastrointestinal | Negative | No nausea, vomiting or constipation |
| Integumentary | Negative | Scalp healed; no redness under the new arrays this morning |
| Neurological | Negative | No headache, seizure, speech change or weakness |
| Hematologic and lymphatic | Negative | No bruising or bleeding |
| Respiratory | Negative | No cough or breathlessness |
| Psychiatric | Negative | More hopeful; PHQ-9 6; no thoughts of self-harm |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day | Two tablets every 6 hours as needed | Oral route | 1994-06-29 | active | S |
| Dexamethasone 4 mg oral tablet, one tablet twice a day with food, for symptomatic vasogenic edema, until surgery | One tablet twice a day with breakfast and lunch | Oral route | 1994-06-30 to 1994-07-08 | completed | S |
| Famotidine 20 mg oral tablet, one tablet twice a day while taking dexamethasone | One tablet twice a day | Oral route | 1994-06-30 to 1994-08-12 | completed | S |
| Dexamethasone 2 mg oral tablet, one tablet twice a day after surgery, tapering | One tablet twice a day | Oral route | 1994-07-10 to 1994-07-29 | completed | S |
| Dexamethasone 2 mg oral tablet: one tablet daily for one week, then half a tablet daily for one week, then stop | One tablet daily for a week, then half a tablet daily for a week | Oral route | 1994-07-29 to 1994-08-12 | completed | S |
| Temozolomide 140 mg oral capsule, 140 mg (75 mg/m2) by mouth daily at bedtime on an empty stomach, seven days a week for 42 days from the first day of radiotherapy | Once daily at bedtime, seven days a week, for 42 days | Oral route | 1994-08-03 to 1994-09-13 | completed | S |
| Sulfamethoxazole 800 mg and trimethoprim 160 mg oral tablet, one tablet three times a week (Monday, Wednesday and Friday) to prevent Pneumocystis pneumonia | One tablet on Monday, Wednesday and Friday | Oral route | 1994-08-03 | active | S |
| Ondansetron 8 mg oral tablet, one tablet 30 to 60 minutes before each temozolomide dose, and every 8 hours as needed for nausea | Before each temozolomide dose; every 8 hours as needed | Oral route | 1994-08-03 | active | S |
| Temozolomide 140 mg oral capsule, 280 mg (150 mg/m2) by mouth at bedtime on days 1 to 5 of each 28-day cycle, adjuvant cycle 1 of 6 | Two capsules once daily at bedtime on days 1 to 5 of each 28-day cycle | Oral route | 1994-10-09 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1994-10-09 | Body height | 180 | cm | S |
| 1994-10-09 | Body weight | 66.6 | kg | S |
| 1994-10-09 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 1994-10-09 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1994-10-09 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1994-10-09 | Heart rate | 74 | /min | S |
| 1994-10-09 | Respiratory rate | 14 | /min | S |
| 1994-10-09 | Body temperature | 36.6 | Cel | S |
| 1994-10-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1994-10-09 | Hemoglobin [Mass/volume] in Blood | 12.2 | g/dL | 12-15.5 g/dL | Normal | S |
| 1994-10-09 | Leukocytes [#/volume] in Blood by Automated count | 4.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1994-10-09 | Neutrophils [#/volume] in Blood by Automated count | 2.9 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1994-10-09 | Lymphocytes [#/volume] in Blood by Automated count | 0.6 | 10*3/uL | 1-4 10*3/uL | Low | S |
| 1994-10-09 | Platelets [#/volume] in Blood by Automated count | 168 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1994-10-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.81 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1994-10-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1989)/1.73 sq M | 86 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1994-10-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-35 U/L | Normal | S |
| 1994-10-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 8-35 U/L | Normal | S |
| 1994-10-09 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1994-10-09 | Glucose [Mass/volume] in Serum or Plasma | 91 | mg/dL | 70-99 mg/dL | Normal | S |
| 1994-10-09 | Karnofsky Performance Status score | 80 | {score} | S | ||
| 1994-10-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S |
Vital signs recorded on 1994-10-09; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 66.6 kg; blood pressure 120/76, pulse 74 |
| Head | Scalp shaved for the arrays; skin intact; radiation dermatitis resolved |
| Neurological | Speech fluent; strength full in all four limbs; gait steady |
| Extremities | No leg swelling or calf tenderness |
| Psychiatric | Engaged and composed |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Three weeks of headaches on waking, with ten days of pauses in finding words and clumsiness of the right hand, in a previously well woman of 54: an intracranial lesion must be excluded. MRI of the brain with and without contrast booked for tomorrow morning, and neuro-oncology review booked | resolved | confirmed | R29.818 | S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded when the MRI showed a brain mass. |
| Left posterior frontal ring-enhancing mass, 3.8 cm, with central necrosis, surrounding edema and 5 mm midline shift, next to the language and motor areas; presumed high-grade glioma, with no primary cancer elsewhere on CT; tissue diagnosis pending | resolved | confirmed | D49.6 | S — Synthetic imaging diagnosis before surgery; superseded by the pathology. |
| Glioblastoma, IDH-wildtype, CNS WHO grade 4, left posterior frontal lobe, MGMT promoter methylated, after gross total resection of the enhancing tumor; synthetic modern detail linked to her publicly reported brain cancer | active | confirmed | C71.1 | S — Synthetic histology, molecular result and location; brain cancer is documented as the cause of her death (D), and nothing more about it was made public. |
| Late effects of childhood poliomyelitis: paralysis of the left leg in early childhood, treated with a metal brace, a special shoe, massage and heat, with full recovery of walking by about age 12 and a later career as an Olympic sprinter; no new weakness, fatigue or pain now to suggest post-polio syndrome | active | confirmed | B91 | S — Documented childhood polio (D); the current absence of new symptoms is synthetic. |
| Vasogenic cerebral edema around the left frontal mass, with 5 mm midline shift, causing headache and contributing to the language and right-hand symptoms; treated with dexamethasone | resolved | confirmed | G93.6 | S — Synthetic finding on the first MRI. |
| Steroid-induced hyperglycemia on dexamethasone: random glucose 168 mg/dL, with an A1c of 5.6% before steroids | resolved | confirmed | R73.9 | S — Synthetic common effect of dexamethasone; resolved after the taper. |
| Lymphopenia from temozolomide, grade 2 (absolute lymphocytes 0.5 x 10^3/uL at the end of chemoradiation): Pneumocystis prophylaxis continues until recovery to grade 1 or better | active | confirmed | D72.810 | S — Synthetic common effect of daily temozolomide with radiotherapy. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | MRI of the brain after chemoradiation (RANO 2.0) | About four weeks after radiotherapy, then every two to three months | Up to date | Two days ago: treatment-related change, no progression; new baseline |
| Imaging | Next MRI of the brain | Every two to three months during adjuvant treatment | Due | After cycle 2 |
| Laboratory | Blood count with neutrophils, lymphocytes and platelets | Before each adjuvant cycle and on day 22 | Completed today | Hemoglobin 12.2 g/dL, white cells 4.4, neutrophils 2.9, lymphocytes 0.6, platelets 168: cycle 1 can start |
| Laboratory | Day-22 blood count | Day 22 of each adjuvant cycle, then weekly until neutrophils exceed 1.5 | Due | Booked for the preventive visit three weeks from now |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Before each cycle and midway through cycle 1 | Completed today | ALT 31, AST 27 U/L, bilirubin 0.5 mg/dL; the grade 1 rise has resolved |
| Laboratory | Liver tests midway through adjuvant cycle 1 | Midway through the first cycle | Deferred | A planned deviation: to spare her an extra trip, the mid-cycle liver tests will be drawn with the day-22 blood count, about a week after the label's midpoint. Today's liver tests are normal after a grade 1 rise. Outcome and action to be recorded at that draw |
| Laboratory | Kidney function and glucose | Each visit | Completed today | Creatinine 0.81 mg/dL, eGFR 86; glucose 91 mg/dL |
| Medication safety | Pneumocystis pneumonia prophylaxis | Until lymphopenia is grade 1 or better | Completed today | Continues for lymphocytes 0.6 |
| Medication safety | Antiemetic before temozolomide | Each dose | Completed today | Ondansetron before each bedtime dose |
| Self-management | Tumor-treating fields: wear time and scalp care | Each visit while in use | Completed today | Started yesterday; at least 18 hours a day; shave and shift arrays at each change; report redness or blisters |
| Examination | Neurologic examination (language, strength, gait) | Each visit | Completed today | No deficit |
| Medication safety | Seizure history and antiseizure drug need | Each visit | Not indicated | No seizure; no antiseizure drug |
| Examination | Signs of leg clot or pulmonary embolism | Each visit | Completed today | None |
| Survey | Performance status (Karnofsky) | Each visit | Completed today | Karnofsky 80 |
| Referral | Palliative care | Early and ongoing | Up to date | Seen eleven days ago; advance directive completed; follow-up in two months |
| Self-management | Falls, leg strength and late effects of polio | Each visit | Completed today | No falls; legs strong; walking daily |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, each treatment phase, and when symptoms change | Completed today | PHQ-9 6; no thoughts of self-harm |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (2026); Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18(3):170-186 (PMID 33293629) (2021); Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996 (PMID 15758009) (2005); Stupp R, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma (EF-14). JAMA 2017;318(23):2306-2316 (PMID 29260225) (2017); Wen PY, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 2023 (PMID 37774317) (2023); TEMODAR (temozolomide) capsules, prescribing information (2026); Walbert T, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol 2021;23(11):1835-1844 (PMID 34174071) (2021); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023); Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024); Farbu E, et al. EFNS guideline on diagnosis and management of post-polio syndrome. Eur J Neurol 2006;13(8):795-801 (PMID 16879288) (2006); CMID: Clinical Monitoring Intelligence Database, depression monograph (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Temozolomide days 1 to 5 from tonight. Preventive visit and day-22 blood count with liver tests in three weeks. Neuro-oncology review and MRI after cycle 2. Call for fever, bruising, a seizure, headache, new weakness or scalp blisters. Next scheduled visit 1994-10-29: periodic adult preventive visit. [S]